When Rate-Control Drugs Fail in Atrial Fibrillation: Ablation, and Which Pacemaker
A single patient whose medications have genuinely run out of room to help. The disagreement isn't about whether to proceed with ablation and a pacemaker anymore — it's about which pacing method serves someone who's about to be paced almost all the time.
T.G., a 71-year-old woman, has kept a vegetable garden behind her house for over thirty years, but this past summer was the first time she couldn't keep up with the weeding on her own, tiring out after only a few rows even in the cool of the morning. She has permanent atrial fibrillation and hypertension, well controlled on medication for years, but her fibrillation's ventricular rate has become persistently, symptomatically rapid despite genuinely maximized rate-control therapy — metoprolol at her highest tolerated dose, digoxin added and confirmed therapeutic, and a trial of diltiazem that had to be stopped for symptomatic hypotension. Nothing left in the standard rate-control toolbox has controlled her rate, and her symptoms and fatigue have escalated in step with it.
With medical rate control genuinely exhausted, the team and T.G. have agreed on AV-node ablation paired with a permanent pacemaker — deliberately destroying the AV node's own conduction and replacing it entirely with a device, which reliably resolves the rate-control problem since there's no longer any native conduction left to run fast. What's still being decided is which pacing method to use, because unlike most pacemaker patients, she'll be paced essentially all the time once her AV node is gone, and conventional right-ventricular pacing carries a real, dose-dependent risk of its own kind of cardiomyopathy when the pacing burden runs this high. She has already told the team plainly that she just wants her garden back, and understands the ablation itself is the part that gets her there — the pacing-method conversation is one she's trusting them to have on her behalf.
Nearly full-time pacing, and which kind
I'd use conduction-system pacing — His-bundle or left bundle branch area pacing — rather than conventional right-ventricular pacing. She's going to be paced close to a hundred percent of the time once her AV node is ablated, and at that burden, conventional RV pacing carries a real, well-documented risk of inducing its own pacing-related cardiomyopathy from the dyssynchrony it creates. Her ejection fraction is already mildly reduced; I don't want to add a second mechanism of decline on top of the one we're fixing.
I agree conventional RV pacing is the wrong default at this burden, but I don't think conduction system pacing is the only alternative worth naming. It has a real learning curve and a higher lead- revision rate than conventional pacing in most published series, and cardiac resynchronization therapy — biventricular pacing — is also a reasonable option at her anticipated pacing burden, with a longer track record specifically in patients already carrying some ejection-fraction reduction the way she is.
That's a fair addition, not really a disagreement with the core point — we're aligned that conventional RV pacing is the option to avoid here. The real question is which of the two alternatives an individual implanting physician's experience and her anatomy actually favor, and that's reasonably left to the day of the procedure rather than settled definitively in clinic today.
Worth confirming for the record that this wasn't a shortcut around medical therapy — her rate-control regimen was genuinely maximized first: metoprolol at her highest tolerated dose, digoxin added and titrated to a level of 0.8, inside the 0.5 to 0.9 nanogram-per-milliliter window that applies in atrial fibrillation — the older, wider range runs into a mortality signal — and diltiazem tried and appropriately stopped when it caused symptomatic hypotension. Going forward, once the AV node is ablated, none of those agents have any native conduction left to slow. Digoxin and diltiazem come off outright. Metoprolol is the one that needs care: it has been part of her blood pressure control for years, and stopping a maximal dose abruptly invites rebound hypertension and tachycardia, so it gets tapered over one to two weeks and reassessed as an antihypertensive rather than simply deleted. One programming point belongs in the same conversation — her device should be set to pace at an elevated lower rate, on the order of ninety beats per minute, for the first weeks after ablation and stepped down gradually, because the abrupt change in rate after AV-node ablation carries a recognized risk of pause-dependent polymorphic ventricular tachycardia. Her anticoagulation continues unchanged; ablating the AV node doesn't touch her stroke risk from the fibrillation itself, which is still very much present in her atria.
AV-node ablation and pacemaker implantation confirmed as the plan, with conventional right- ventricular pacing ruled out given her anticipated near-continuous pacing burden. The specific choice between conduction-system pacing and cardiac resynchronization therapy was left to the implanting physician's judgment at the time of the procedure rather than fixed in advance. Digoxin and diltiazem to be stopped once the ablation is performed, with metoprolol tapered over one to two weeks rather than withdrawn abruptly and reassessed as an antihypertensive. Device to be programmed to an elevated lower rate for the first weeks post-ablation and stepped down gradually. Apixaban continues at full dose, unchanged.